Jeff Ryckman
@jryckman3
Followers
5K
Following
22K
Media
2K
Statuses
12K
Medical Physicist ➡️ MD | Dedicated to LR-PFS 🎯, QoL, isotoxicity ⚖️, constraints 🙅♀️, & reproducibility 📊 | Creator of @RadOncReview | #RadOncCalc
Joined October 2009
Excited for this and truly thankful for the opportunity! 🙏 #radonc.
Our #ACROpolis partners at @RadoncROVER are hosting their next session on oligomets on September 5 at 3 p.m. ET with Drs. @jryckman3 and @AlexSherryMD. Registration is now open:
0
1
18
RT @jryckman3: Fantastic update to a standout 2022 paper with lots of new insights. Highly recommend a read!. Catch a brief discussion on d….
0
3
0
RT @TheDrWood: @NiuSanford @lemmiwenks Yes, @ASTRO_org should have publicly honored Dr. Bradford Perez by now (it’s been more than a decade….
0
4
0
RT @EChrisDee: 📜 Led by Dr @Jonas_Willmann, we validate distant metastasis velocity in international cohorts, underscoring #metastatic #tra….
0
3
0
RT @jonas_willmann: @RadOncUSZ @IJROBP 8/ Results — WFFS (repeat OMD only):. ✅SABR-5: trend toward shorter WFFS with high DMV (NS). ✅CORE:….
0
2
0
Fantastic update to a standout 2022 paper with lots of new insights. Highly recommend a read!. Catch a brief discussion on disease pace/velocity in context of a real-world case at @ACRORadOnc ROVER Sept 5 at 9–10 pm CEST / 3–4 pm EST. Hope to see you there! #radonc
Distant failure after SBRT for oligometastatic disease is a common pattern of progression. Yet, we lack validated post-progression models to guide treatment. We tested whether Distant Metastasis Velocity (DMV) can fill this gap - and validated it across multinational cohorts 🧵
0
3
10
RT @jonas_willmann: Distant failure after SBRT for oligometastatic disease is a common pattern of progression. Yet, we lack validated post….
0
16
0
RT @aiims2738: I’m beyond excited to join Moffitt Cancer Center as an Assistant Member in Radiation Oncology @MoffittNews 🔥 #radonc .🎯 Thri….
0
10
0
RT @jryckman3: @drdanchoi So true. Healthcare in America is broken because Congress gives its time to the biggest lobbying budgets - corpor….
0
2
0
RT @drdanchoi: Story time: I went to DC in 2019 to try to meet with Congress members about No Surprises Act. Not seeing patients for a coup….
0
216
0
RT @TonyFelefly: @jryckman3 @IJROBP @isteddos @krishnan_patel @RTendulkarMD @VedangMurthy @piet_ost @weeloonong Nice work! .Looks very rand….
0
1
0
RT @changjeesuk1: @jryckman3 @emmadunne I 1000% agree. Dr.Liu confirmed it was 110% with VMAT style initially, now 120%. (At BCCA, 150% me….
0
1
0
RT @KaramLab: @DavidSherMD @changjeesuk1 @emmadunne Do you really need to 😊? More dose Or less? I’d argue it depends on the combination an….
0
1
0
RT @drdavidpalma: Interesting case report in the Green Journal showing lung function changes after SBRT - you can see how the contralateral….
0
24
0
RT @DavidSherMD: @changjeesuk1 @emmadunne Very interesting paper and unique data. I am struck by the relatively poor local control (66% i….
0
3
0
RT @changjeesuk1: Sometimes we use 30Gy/5, regardless of the reason. Here’s a great paper showing what kind of local control we can expect….
0
22
0
RT @Xristodouleas: Reducing PTV margins in #ProstateCancer #SBRT can help mitigate toxicity. But margins shouldn’t be reduced blindly. Pro….
0
12
0
RT @Timothee_MD: Recent @WSJ articles are deeply problematic, Ccongrats again @kevinnbass for unveiling it!. It feels like ��When wolves are….
0
2
0
RT @kevinnbass: It turns out to be enrolled in Replimune's trial and be considered "non-responsive", you had to undergo eight weeks of immu….
0
2
0
RT @SprakerMDPhD: @jryckman3 @olusolaodavies I've never met an RO that is against the modality. I have used it and refer out as well. ROs….
0
1
0